Synairgen (SNG)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

162.40p
   
  • Change Today:
    -3.00p
  • 52 Week High: 224.66
  • 52 Week Low: 77.00
  • Currency: UK Pounds
  • Shares Issued: 201.34m
  • Volume: 482,497
  • Market Cap: 326.98m
  • RiskGrade: 510

Synairgen Overview

Synairgen is in the pharma and biotech sector and is currently trading at 162.40p per share. In the last year Synairgen's share price has ranged from 77.00p to 224.66p and brokers are currently rating this stock as 'strong buy'.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 2.3%
Div Cover n/a 25.0
Op Mrgn n/a 79.5%
ROCE n/a  
Latest F'cast
P/E n/a 1.7
PEG n/a n/a
Pr/Revenue n/a 1.2
Pr/Book 3.9  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Synairgen Fundamentals

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-16 n/a (3.40) (3.06)p n/a n/a n/a n/a 0.0%
31-Dec-17 5.03 1.63 1.92p 5.6 n/a n/a n/a 0.0%
31-Dec-18 0.10 (4.10) (3.45)p n/a n/a n/a n/a 0.0%
31-Dec-19 n/a (4.79) (3.53)p n/a n/a n/a n/a 0.0%
31-Dec-20 n/a (17.73) (9.46)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Synairgen Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-21 293.00 233.00 99.90p 1.7 n/a n/a 4.00p 2.3%
31-Dec-22 582.50 512.50 220.00p 0.8 0.0 +120% 5.00p 2.9%

Copyright © 2021 FactSet Research Systems Inc. All rights reserved.

Synairgen Company Announcements

Synairgen Notice of Interim Results 21-Sep-2021 07:00 RNS
Holding(s) in Company 10-Sep-2021 11:30 RNS
Exercise of Options and Total Voting Rights 12-Aug-2021 16:12 RNS

Latest Synairgen Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Synairgen Market Data

Currency UK Pounds
Share Price 162.40p
Change Today -3.00p
% Change -1.81 %
52 Week High 224.66
52 Week Low 77.00
Volume 482,497
Shares Issued 201.34m
Market Cap 326.98m
RiskGrade 510

Synairgen Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
46.59% above the market average46.59% above the market average46.59% above the market average46.59% above the market average46.59% above the market average
92.00% above the sector average92.00% above the sector average92.00% above the sector average92.00% above the sector average92.00% above the sector average
Price Trend
2% below the market average2% below the market average2% below the market average2% below the market average2% below the market average
16.13% above the sector average16.13% above the sector average16.13% above the sector average16.13% above the sector average16.13% above the sector average
Income
5.09% above the market average5.09% above the market average5.09% above the market average5.09% above the market average5.09% above the market average
63.64% above the sector average63.64% above the sector average63.64% above the sector average63.64% above the sector average63.64% above the sector average
Growth Not Available

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Synairgen Dividends

No dividends found

Trades for 21-Sep-2021

Time Volume / Share Price
11:37 5,928 @ 161.87p
11:30 113 @ 162.40p
11:30 1,934 @ 162.40p
11:30 1,773 @ 162.40p
11:30 1,170 @ 162.40p

Synairgen Key Personnel

CEO Richard J Marsden
Finance Director John C Ward

Top of Page